

Keystone First VIP Choice specifications for gaps in care Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)

The purpose of this measure is to identify and track members who have been diagnosed with rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease-modifying anti-rheumatic drug (DMARD).

<p>Which members are included? (denominator)</p>	<ul style="list-style-type: none"> Members 18 years old or older with active coverage with the health plan as of the last day of the reporting period. Members eligible for the prescription drug benefit during the reporting period. Members with at least two provider visits for rheumatoid arthritis between the reporting period start date and 31 days prior to the reporting period end date.
<p>What provider data is included? (numerator)</p>	<ul style="list-style-type: none"> Members who had at least one ambulatory prescription dispensed for a DMARD during the reporting period.
<p>Provider communication tools (how providers receive the information)</p>	<p>Claims data is evaluated monthly for all members. In the event that there is no claim for this specific service, the system generates an automatic notice of care gap. Care gap status notification is provided by and accessible through NaviNet via:</p> <ul style="list-style-type: none"> Member eligibility pop-up alerts. Care gap query reports. Member clinical summary reports. Monthly NaviNet report updates, which reflect gaps in care for primary care provider practice panel membership. Panel membership results, which include indicators for this gaps in care measure as Missing, Up-to-date, or Overdue.

